Psoriasis News and Research

Latest Psoriasis News and Research

Workshop to help physicians and clinicians increase job satisfaction and prevent burnout

On Saturday, May 11, the Center for Mindfulness at University of California, San Diego School of Medicine is hosting a workshop to help physicians and clinicians increase job satisfaction and prevent burnout. The program will show participants how to incorporate the concept of mindfulness into their daily clinical practice with the long-term goal of enhancing patient-centered care and physician well-being through compassionate communication.

4 Mar 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

‘Traffic light’ guide for pediatric bacterial infection needs refining

Study results suggest that a “traffic light” system for categorizing the severity of infections in children fails to detect a substantial number of serious bacterial infections, particularly urinary tract infections.

26 Feb 2013

4SC Discovery enters exclusive research and license agreement with LEO Pharma

LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.

26 Feb 2013

Dress to impress in the ICU

Dressing in “traditional” medical attire may help physicians in the intensive care unit to get relationships with their patients’ families off to a good start, research suggests.

20 Feb 2013

Severe childhood asthma blood test hopes dashed

Blood eosinophil counts do not reliably reflect airway eosinophil concentrations in children with severe, therapy-resistant asthma, and therefore cannot be used to make therapeutic decisions, researchers report.

19 Feb 2013

Oxidative stress: the price of sucrose pain relief in neonates

Although sucrose significantly reduces the pain experienced by preterm neonates undergoing heel lance, it is associated with significant increases in adenosine triphosphate use and oxidative stress, the results of a US study indicate.

19 Feb 2013

Risk factors for invasive candidiasis in infants clarified

A combination of exposure to broad-spectrum antibiotics and having a platelet count below 50,000/mm3 significantly increases a low-to-normal–weight infant’s chance for developing invasive candidiasis, report researchers.

19 Feb 2013

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

March is National Autoimmune Disease Awareness Month 2013. To mark the annual event, the American Autoimmune Related Diseases Association Inc. (AARDA) is encouraging the national and local media around the country to report stories on autoimmune diseases (AD) and autoimmunity as a category of disease.

13 Feb 2013

Large deviations from oxygen saturation targets for preterm infants

Recommended oxygen saturation targets are not always followed accurately during the first few minutes after the birth of preterm infants, show results of a study published in Resuscitation.

12 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013